Forxiga 5 mg film-coated tablets

DRUG5 trials

Sponsors

University Medical Center Groningen, Universitaetsmedizin Goettingen, Center For Outcomes Research And Clinical Epidemiology S.r.l., Humanitas Mirasole S.p.A., Universitair Medisch Centrum Groningen

Conditions

Alport syndromeChronic Kidney DiseaseMyocardial InfarctionType 1 DiabetesType 2 diabetes mellitusdiabetes mellitus

Phase 2

ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

WithdrawnCTIS2023-504404-28-00

University Medical Center GroningenChronic Kidney Disease, Type 1 Diabetes

Target: 26Updated: 2026-02-03

ASPIRE-1; Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

Not yet recruitingCTIS2026-525684-40-01

Universitair Medisch Centrum GroningenChronic Kidney Disease, Type 1 Diabetes

Target: 10Updated: 2026-10-09

Phase 3

DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dapagliflozin on the progression of chronic kidney disease in adolescent and young adult patients with Alport syndrome

RecruitingCTIS2023-508502-18-00

Universitaetsmedizin GoettingenAlport syndrome

Start: 2024-03-19Target: 102Updated: 2025-10-16

Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus

Not yet recruitingCTIS2025-523375-29-00

Humanitas Mirasole S.p.A.diabetes mellitus, Myocardial Infarction

Target: 300Updated: 2026-02-06

Phase 4

Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.

CompletedCTIS2024-518915-20-00

Center For Outcomes Research And Clinical Epidemiology S.r.l.Type 2 diabetes mellitus

Start: 2022-02-16End: 2025-10-02Target: 1167Updated: 2025-09-30

Related Papers

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.

2025-04-0115 citations